Zoetis Inc. Share Price Sao Paulo

Equities

Z1TS34

BRZ1TSBDR006

Pharmaceuticals

Delayed Sao Paulo 17:34:28 05/06/2024 BST 5-day change 1st Jan Change
58.11 BRL +22.91% Intraday chart for Zoetis Inc. +3.45% -3.93%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 9.15B 48.34B 716B Sales 2025 * 9.77B 51.59B 764B Capitalization 78.43B 414B 6,137B
Net income 2024 * 2.48B 13.13B 194B Net income 2025 * 2.76B 14.59B 216B EV / Sales 2024 * 9.03 x
Net Debt 2024 * 4.18B 22.06B 327B Net Debt 2025 * 3.49B 18.41B 273B EV / Sales 2025 * 8.39 x
P/E ratio 2024 *
31.6 x
P/E ratio 2025 *
28.5 x
Employees 14,100
Yield 2024 *
1%
Yield 2025 *
1.14%
Free-Float 90.81%
More Fundamentals * Assessed data
Dynamic Chart
1 day+22.91%
1 week+3.45%
Current month+5.85%
1 month+10.90%
3 months+1.11%
6 months+5.50%
Current year-3.93%
More quotes
1 week
55.93
Extreme 55.93
58.11
1 month
52.19
Extreme 52.19
58.11
Current year
47.10
Extreme 47.1
62.34
1 year
47.10
Extreme 47.1
62.34
3 years
40.59
Extreme 40.5875
88.50
5 years
35.80
Extreme 35.8
88.50
10 years
35.80
Extreme 35.8
88.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 31/12/11
Director of Finance/CFO 52 31/05/21
Chief Tech/Sci/R&D Officer - 31/12/10
Members of the board TitleAgeSince
Chairman 71 31/12/12
Director/Board Member 73 31/07/13
Director/Board Member 74 31/05/13
More insiders
Date Price Change Volume
05/06/24 58.11 +22.91% 50
04/06/24 56.36 +0.34% 1,807
03/06/24 56.17 +2.31% 148
28/05/24 54.9 +0.68% 2,069

Delayed Quote Sao Paulo, June 05, 2024 at 05:34 pm

More quotes
Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows: - pets (64.4%): cats and dogs (94.9% of net sales) and horses (5.1%); - livestock (34.5%): cattle (51.6% of sales), swine (20.2%), poultry (17.1%), fish (7.6%) and other (3.5%); - other (1.1%). Net sales break down by family of products into parasiticides (23%), vaccines (21.3%), dermatological products (16.4%), anti-infectives (13.4%), medical food additives (4.5%), diagnostic products (4.4%) and other (17%). At the end of 2022, the group has 29 production sites worldwide. The United States accounts for 53.4% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
171.9 USD
Average target price
211.2 USD
Spread / Average Target
+22.88%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW